Hydromorphone

Introduction Overview

Generic Name

hydromorphone

Brand Name

Dilaudid

Dosage Form

oral liquid (1 mg/mL), oral tablet (2 mg; 4 mg; 8 mg), oral extended-release tablet (8 mg; 12 mg; 16 mg; 32 mg)

Drug Class

Opioids (narcotic analgesics)

Pharmacokinetics

Hydromorphone is an opioid analgesic with distinct pharmacokinetic properties that influence its clinical use.

Absorption: Hydromorphone is well absorbed when administered orally, though it undergoes significant first-pass metabolism that reduces bioavailability. The oral liquid and immediate-release tablets offer rapid onset of analgesia, typically within 30 minutes, with peak plasma concentrations attained between 30 minutes to one hour post-dose. Extended-release formulations maintain steadier plasma concentrations over 12-24 hours, supporting around-the-clock pain management. Factors such as food intake can slightly delay absorption but generally do not affect overall bioavailability.

Distribution: Following absorption, hydromorphone is widely distributed throughout body tissues, with a volume of distribution approximately 1.22–4.94 L/kg. It exhibits moderate plasma protein binding (~8-19%), primarily to albumin. The drug crosses the blood-brain barrier effectively, accounting for its potent central analgesic effects. Hydromorphone also crosses the placental barrier and is secreted in breast milk, necessitating caution in pregnancy and lactation.

Metabolism: Hydromorphone undergoes extensive hepatic metabolism primarily via phase II conjugation pathways, mainly glucuronidation by UDP-glucuronosyltransferases (UGT2B7) to form hydromorphone-3-glucuronide, an inactive metabolite. This metabolite is pharmacologically inactive but can accumulate in renal impairment, potentially contributing to neurotoxic effects. Unlike many opioids, hydromorphone has minimal involvement with cytochrome P450 enzymes, lowering the potential for cytochrome-mediated drug interactions.

Elimination: The elimination half-life of hydromorphone ranges between 2 and 3 hours following oral administration. Excretion is primarily renal, with approximately 40-50% of the active drug and metabolites excreted via urine and smaller amounts via feces. In patients with renal or hepatic impairment, clearance may be reduced, necessitating dose adjustments to prevent accumulation and toxicity. Hydromorphone’s pharmacokinetic profile allows for flexible dosing but requires careful monitoring in vulnerable populations.

Dosage Forms

Available Dosage Forms:
- Oral liquid formulation: 1 mg/mL concentration suitable for titration and patients unable to swallow tablets.
- Oral immediate-release tablets: Available in 2 mg, 4 mg, and 8 mg strengths designed for acute pain management requiring rapid onset.
- Oral extended-release tablets: Available in 8 mg, 12 mg, 16 mg, and 32 mg strengths formulated for sustained, around-the-clock analgesia in chronic moderate to severe pain.

Dosages for Adults and Adolescents:
- Immediate-release hydromorphone is typically initiated at 2-4 mg orally every 4 to 6 hours as needed for pain, with titration based on efficacy and tolerability.
- Extended-release hydromorphone tablets are reserved for opioid-tolerant patients requiring continuous analgesia. Dosing starts at levels equianalgesic to previous opioid regimens and adjusted individually, often administered every 12 or 24 hours.

Specific Patient Populations:
- Patients with renal insufficiency require cautious dosing and extended dosing intervals due to reduced clearance of hydromorphone-3-glucuronide.
- Hepatic impairment demands dose reduction and careful monitoring due to altered metabolism.
- Use in elderly patients warrants lower starting doses and slower titration to minimize risks of sedation and respiratory depression.
- Hydromorphone dosing during pregnancy and lactation is generally avoided or used only when benefits outweigh risks, due to potential neonatal withdrawal and opioid toxicity.
- Pediatric use of hydromorphone oral formulations is limited and guided by specialist consultation.

Clinical Guidelines:
- Extended-release tablets should never be used on an as-needed basis for acute pain to prevent overdose and adverse events.
- Oral formulations must be swallowed whole; crushing or chewing can result in rapid release and absorption, causing fatal overdose.
- Liquid dosing requires precise measurement with supplied devices to ensure accurate dosing.
- Dose adjustments should be individualized based on pain severity, previous opioid exposure, and patient response.

Mechanism Of Action

Hydromorphone exerts its analgesic effects primarily through its action as a potent agonist at the μ-opioid receptors located in the central nervous system (CNS). Upon binding to these G-protein coupled receptors, hydromorphone activates intracellular signaling pathways that inhibit adenylate cyclase activity, leading to decreased cyclic AMP levels. This sequence reduces neurotransmitter release and neuronal excitability, effectively modulating pain perception at the spinal cord and brain levels.

At the cellular level, activation of μ-opioid receptors by hydromorphone induces opening of potassium channels and closing of calcium channels, resulting in hyperpolarization of neuronal membranes and inhibition of nociceptive neurotransmitter release such as substance P, glutamate, and calcitonin gene-related peptide. These actions interrupt pain signal transmission within ascending pathways and enhance descending inhibitory pain pathways.

Biochemically, hydromorphone’s high affinity for μ-opioid receptors, combined with moderate lipophilicity, facilitates rapid CNS penetration and robust receptor binding. Unlike some opioids, hydromorphone lacks significant activity at δ or κ-opioid receptors, conferring a relatively selective profile for μ-receptor-mediated analgesia. Research indicates that hydromorphone’s metabolite, hydromorphone-3-glucuronide, does not possess opioid activity but may contribute to neuroexcitation at high concentrations.

Clinically, hydromorphone’s mechanism translates to effective relief of moderate to severe pain, including acute postoperative pain and chronic cancer-related pain. Compared with morphine, hydromorphone offers greater potency and may produce less histamine release, potentially reducing adverse effects like pruritus and hypotension. Clinical studies support its use in patients intolerant to other opioids or requiring potent analgesia. Ongoing research investigates its receptor binding kinetics and potential for opioid-sparing regimens in multimodal pain management.

Pharmacological Actions

Potent μ-opioid receptor agonist providing central analgesic effects
Inhibits ascending pain pathways by decreasing neurotransmitter release
Enhances descending inhibitory pain pathways to modulate pain perception
Induces neuronal hyperpolarization by modulating ion channel activity
Produces analgesia primarily without significant activity at κ or δ receptors
Exerts sedative properties resulting in drowsiness and decreased anxiety
May cause respiratory depression by acting on brainstem respiratory centers
Suppresses cough reflex through medullary cough centers at higher doses
Causes miosis through parasympathetic stimulation of the Edinger-Westphal nucleus
Reduces gastrointestinal motility leading to constipation
Has central antidiuretic hormone releasing effects causing urinary retention
Exhibits a rapid onset and relatively short duration in immediate-release forms
Extended-release forms maintain prolonged analgesia for chronic pain
Displays potential for developing tolerance and physical dependence
Minimal histamine release compared to other opioids, lowering risk of hypotension

Therapeutic Or Clinical Uses

Management of moderate to severe acute pain requiring opioid analgesia
Treatment of chronic pain in opioid-tolerant patients with extended-release formulations
Analgesia in postoperative settings where effective pain control is critical
Use in cancer-related pain syndromes requiring potent opioid therapy
Alternative opioid for patients intolerant to morphine or other opioids
Palliative care for intractable pain to improve quality of life
Adjunctive treatment when non-opioid analgesics are insufficient
Sometimes employed in anesthesia adjunct protocols for pain control
Use in severe trauma or burn patients requiring strong analgesia
Pain control in patients with renal impairment necessitating an opioid with less active metabolites
Utilized in titrated doses to manage opioid withdrawal symptoms in some protocols (off-label)
Treatment of dyspnea associated with terminal illness (off-label use)
Short-term pain management in patients with limited oral intake using liquid formulations
In-hospital treatment of pain where close monitoring of opioid effects is available
Use with careful dosing adjustments in elderly patients with chronic pain

Side Or Adverse Effects

Respiratory depression which can be life-threatening if untreated
Sedation and drowsiness impairing cognitive and motor functions
Nausea, vomiting, and gastrointestinal discomfort
Constipation due to decreased gastrointestinal motility
Dizziness and light-headedness increasing fall risk
Pruritus (itching) often related to opioid receptor activation or histamine release
Flushing and sweating from cutaneous vasodilation
Headache and occasional migraines
Dry mouth and difficulty swallowing
Urinary retention resulting from anticholinergic effects
Confusion or delirium, especially in elderly or debilitated patients
Tolerance development requiring escalating doses for adequate analgesia
Physical dependence and withdrawal symptoms upon abrupt discontinuation
Serotonin syndrome when combined with serotonergic agents
Potential for opioid-induced hyperalgesia, worsening pain sensitivity

Precautions

Use caution in patients with respiratory disorders such as asthma or COPD
Careful titration advised in elderly or debilitated individuals
Monitor for signs of opioid addiction, abuse, or misuse
Avoid abrupt discontinuation to prevent withdrawal syndrome
Use with caution in patients with head injury or increased intracranial pressure
Monitor adrenal function due to potential cortisol deficiency
Adjust dosing in hepatic or renal impairment to prevent accumulation
Be vigilant for serotonin syndrome when combined with serotonergic drugs
Screen for biliary tract disease as opposed to abdominal pain from other causes
Pregnant women require risk-benefit assessment due to potential neonatal withdrawal
Advise patients about possible sedation impacting driving and operating machinery
Assess potential interactions with other CNS depressants
Inform patients about risks related to opioid overdose and availability of naloxone
Store medication securely to reduce risk of accidental ingestion or misuse
Evaluate suitability in patients with substance use history

Warnings

Misuse can lead to addiction, overdose, or death
Do not use with alcohol or other CNS depressants due to fatal respiratory depression risk
Use during pregnancy may cause life-threatening neonatal withdrawal
Extended-release formulations are not for as-needed pain relief
Risk of fatal respiratory depression is highest during treatment initiation or dose increases
Concomitant use with MAO inhibitors within 14 days is contraindicated
Caregivers should monitor for signs of slow or stopped breathing
Sudden discontinuation may precipitate severe withdrawal symptoms
Crushing or chewing tablets increases risk of overdose
Use caution in patients with sleep apnea syndrome
Potential risk of adrenal insufficiency with long-term use
Can impair mental or physical abilities, increasing accident risk
Overdose risk increased in opioid-naïve individuals
Naloxone should be available for emergency overdose reversal
Do not share medication with others, especially those with substance use disorder

Contraindication

Known hypersensitivity to hydromorphone or other opioids
Severe asthma or significant respiratory depression
Obstruction of the gastrointestinal tract including paralytic ileus
Concomitant or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs)
Patients with acute or severe bronchial asthma in an unmonitored setting
Use in patients with severe hepatic impairment without careful monitoring
Intolerance or allergy to any ingredient in hydro-morphone formulations
Use in patients with bowel obstruction or paralytic ileus
Patients with known hypersensitivity to morphine derivatives
Severe CNS depression or coma
Patients with known or suspected opioid overdose
Use in patients with acute intoxication with alcohol, hypnotics, analgesics
Concurrent use with other CNS depressants without medical supervision
Use in non-opioid-tolerant individuals requiring extended-release formulations
Pregnancy unless clearly necessary due to neonatal risks

Drug Interactions

Concomitant use with benzodiazepines or other CNS depressants increases sedation and respiratory depression risk
MAO inhibitors within 14 days cause hypertensive crisis and serotonin syndrome
Interaction with serotonergic drugs can precipitate serotonin syndrome
Alcohol potentiates CNS and respiratory depressive effects leading to fatal overdose
Other opioid analgesics add to respiratory depression and sedation
Muscle relaxants can enhance CNS depression
Antihistamines may increase sedative and respiratory effects
Drugs that affect cytochrome enzymes generally have minimal interaction but caution advised
CNS depressants like sleep medications amplify sedation and respiratory depression
Stimulants or dopamine agonists may interact variably but require monitoring
Some antiemetics and antidepressants increase risk of serotonin syndrome
Use with caution with drugs affecting gastrointestinal motility
Concomitant use with monoamine oxidase inhibitors contraindicated due to severe hyperadrenergic reactions
Co-administration with drugs affecting opioid metabolism usually poses low risk but monitor clinically
Potential pharmacodynamic interactions with muscle relaxers and anticholinergic agents

Preparations Of The Drug

Oral liquid: 1 mg/mL concentrated solution for precise titration and swallowing difficulties
Immediate-release oral tablets: 2 mg, 4 mg, and 8 mg strengths for acute analgesic use
Extended-release oral tablets: 8 mg, 12 mg, 16 mg, and 32 mg formulations for chronic pain management
Injectable formulations (not covered in oral overview) including hydromorphone hydrochloride injection for parenteral use
Rectal suppositories for patients unable to take oral medications (available in some markets)
Combined products with other analgesics exist but are less commonly used
Pellets or implant formulations under research/clinical trial phases
Packaging includes child-resistant containers to prevent accidental ingestion
Supplied with calibrated measuring devices for liquid preparations to ensure dosing accuracy
Extended-release tablets formulated with abuse-deterrent properties to reduce misuse potential
Commercial preparations require storage at controlled room temperature, protected from moisture and light
Patient information leaflets emphasize proper administration and safety instructions
Some brand names include Dilaudid, Exalgo, Dilaudid-HP, and Palladone
Formulations tailored for titratable dosing in hospitalized and outpatient chronic pain settings
Liquid and immediate release tablets are used for rapid onset; extended-release tablets for maintenance therapy